Rhythm Pharmaceuticals price target lowered to $110 from $125 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $110 from $125 and keeps a Buy rating on the shares, reflecting adjustments to the firm’s long-term sales ramp expectations after Rhythm recently announced its Q4 results and announced additional positive data from its global Phase 3 TRANSCEND trial of setmelanotide in patients with acquired hypothalamic obesity.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
Disclaimer & DisclosureReport an Issue
- Rhythm Highlights Positive Phase 3 Data in Hypothalamic Obesity
- Rhythm Pharmaceuticals price target lowered to $140 from $141 at Canaccord
- Rhythm announces additional data from Phase 3 trial of setmelanotide
- Rhythm Pharmaceuticals price target raised to $143 from $140 at Guggenheim
- Rhythm Pharmaceuticals price target lowered to $136 from $145 at Wells Fargo
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.